Effective UTI management requires understanding of antibiotic pharmacokinetics in the urinary tract, bacterial resistance mechanisms, and host factors that influence treatment outcomes. For uncomplicated lower UTI (cystitis), the goal is to achieve high urinary antibiotic concentrations to eradicate mucosal infection. Nitrofurantoin is reduced by bacterial nitroreductases to highly reactive electrophilic intermediates that attack ribosomal proteins, DNA, and other macromolecules; resistance rates remain remarkably low (<5%) because multiple simultaneous targets must mutate. TMP-SMX provides sequential blockade of the folate synthesis pathway essential for bacterial DNA synthesis, but widespread use has driven E. coli resistance above 20% in many communities. For upper tract infection (pyelonephritis), antibiotics must achieve adequate serum and renal tissue concentrations -- nitrofurantoin and fosfomycin are NOT appropriate because they achieve only urinary concentrations. Fluoroquinolones achieve excellent renal parenchymal penetration through concentration-dependent killing and have a prolonged post-antibiotic effect. Ceftriaxone, a third-generation cephalosporin, inhibits penicillin-binding protein 3 (PBP-3), disrupting cell wall cross-linking; its long half-life (6-9 hours) allows once-daily dosing, and it achieves high renal tissue concentrations making it ideal for empiric pyelonephritis treatment. In complicated UTI, biofilm formation...